Spiriva Handihaler (Tiotropium Bromide) Patent Expiration, LOE Window & CMS Spending
Spiriva Handihaler (Tiotropium Bromide) by Boehringer Ingelheim: FDA Orange Book LOE 2026-07-19, 1 AB generics, $677.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N021395 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-07-19 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $677.1M |
| 2024 Medicare Part D Spend | $486.3M |
| 2024 Medicaid Spend | $190.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.